Io Therapeutics, Inc., Announces Publication of Data on a Novel Compound Promoting Anti-Cancer Immune Responses
September 12, 2023 00:43 ET
|
Io Therapeutics, Inc.
SPRING, Texas, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Io Therapeutics, Inc., announced today the publication in Scientific Reports – Nature Publishing Group, of results from studies done with the...
Io Therapeutics, Inc. Reports Data Demonstrating That the Company's Candidate Treatment for Multiple Sclerosis, IRX4204, Promotes Repair of Damaged Myelin
September 16, 2016 07:00 ET
|
Io Therapeutics, Inc.
SANTA ANA, CA--(Marketwired - Sep 16, 2016) - Io Therapeutics, Inc., today, reported data demonstrating that the company's experimental rexinoid nuclear receptor (RXR) agonist compound, IRX4204,...
Io Therapeutics, Inc. Announces Sponsored Research Agreement With the National Multiple Sclerosis Society Fast Forward Program
August 03, 2015 08:00 ET
|
Io Therapeutics, Inc.
SANTA ANA, CA--(Marketwired - Aug 3, 2015) - Io Therapeutics, Inc. announced today the receipt of funding from the National Multiple Sclerosis Society through Fast Forward to support further...
Io Therapeutics, Inc. Announces Collaboration With The Michael J. Fox Foundation for Parkinson's Research for Evaluation of IRX4204 as a Potential Treatment for Parkinson's Disease
February 26, 2013 13:53 ET
|
Io Therapeutics, Inc.
SANTA ANA, CA--(Marketwire - Feb 26, 2013) - Io Therapeutics, Inc. announced today the initiation of a collaboration with The Michael J. Fox Foundation for Parkinson's Research (MJFF) to evaluate...
IRX4204 as a Potential Disease-Modifying Treatment for Alzheimer's Disease
September 13, 2012 19:30 ET
|
Io Therapeutics, Inc.
SAN FRANCISCO, CA--(Marketwire - Sep 13, 2012) - Io Therapeutics, Inc. announced today the presentation of data from preclinical studies of its Retinoid X Receptor (RXR) agonist compound IRX4204 in...
Io Therapeutics, Inc. Announces Initiation of Dosing in a Phase II Clinical Trial of IRX4204 in Patients With Advanced Prostate Cancer
October 06, 2011 11:00 ET
|
Io Therapeutics, Inc.
SANTA ANA, CA--(Marketwire - Oct 6, 2011) - Io Therapeutics, Inc. announced today initiation of dosing in a phase II clinical trial with its experimental cancer therapeutic, IRX4204, in patients...